Adaptimmune Therapeutics plc (ADAPY)
OTCMKTS · Delayed Price · Currency is USD
0.0508
-0.0041 (-7.47%)
At close: Oct 30, 2025
Adaptimmune Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 65.09 | 178.03 | 60.28 | 27.15 | 6.15 | 3.96 | Upgrade | |
Revenue Growth (YoY) | -53.99% | 195.34% | 122.05% | 341.50% | 55.36% | 252.76% | Upgrade |
Cost of Revenue | 128.69 | 149.13 | 126.51 | 127.73 | 111.09 | 91.57 | Upgrade |
Gross Profit | -63.61 | 28.9 | -66.23 | -100.58 | -104.94 | -87.61 | Upgrade |
Selling, General & Admin | 84.26 | 81.31 | 64.46 | 63.39 | 57.31 | 45.8 | Upgrade |
Operating Expenses | 84.26 | 81.31 | 64.46 | 63.39 | 57.31 | 45.8 | Upgrade |
Operating Income | -147.87 | -52.41 | -130.69 | -163.97 | -162.25 | -133.41 | Upgrade |
Interest Expense | -5.67 | -3.35 | - | - | - | - | Upgrade |
Interest & Investment Income | 5.02 | 6.6 | 5.96 | 1.54 | 1.1 | 2.31 | Upgrade |
Currency Exchange Gain (Loss) | -1.18 | -1.73 | -0.81 | -0.54 | 3.85 | 1.11 | Upgrade |
Other Non Operating Income (Expenses) | - | - | - | - | -0.01 | -0.03 | Upgrade |
EBT Excluding Unusual Items | -149.69 | -50.89 | -125.54 | -162.96 | -157.31 | -130.02 | Upgrade |
Merger & Restructuring Charges | -5.95 | -5.95 | -9.05 | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.01 | 0.09 | Upgrade |
Asset Writedown | -10.4 | -10.4 | - | - | - | - | Upgrade |
Other Unusual Items | - | - | 22.05 | - | - | - | Upgrade |
Pretax Income | -166.05 | -67.24 | -112.54 | -162.96 | -157.3 | -129.93 | Upgrade |
Income Tax Expense | 3.71 | 3.58 | 1.34 | 2.5 | 0.79 | 0.16 | Upgrade |
Net Income | -169.76 | -70.81 | -113.87 | -165.46 | -158.09 | -130.09 | Upgrade |
Net Income to Common | -169.76 | -70.81 | -113.87 | -165.46 | -158.09 | -130.09 | Upgrade |
Shares Outstanding (Basic) | 258 | 252 | 201 | 161 | 156 | 142 | Upgrade |
Shares Outstanding (Diluted) | 258 | 252 | 201 | 161 | 156 | 142 | Upgrade |
Shares Change (YoY) | 8.53% | 25.48% | 24.73% | 3.47% | 9.37% | 35.72% | Upgrade |
EPS (Basic) | -0.66 | -0.28 | -0.57 | -1.03 | -1.01 | -0.91 | Upgrade |
EPS (Diluted) | -0.66 | -0.30 | -0.57 | -1.03 | -1.02 | -0.91 | Upgrade |
Free Cash Flow | -191.67 | -74.09 | -145.56 | -171.27 | 2.16 | -55.93 | Upgrade |
Free Cash Flow Per Share | -0.74 | -0.29 | -0.72 | -1.06 | 0.01 | -0.39 | Upgrade |
Gross Margin | -97.73% | 16.23% | -109.86% | - | - | - | Upgrade |
Operating Margin | -227.19% | -29.44% | -216.81% | -603.97% | -2638.58% | -3370.52% | Upgrade |
Profit Margin | -260.82% | -39.78% | -188.90% | -609.46% | -2570.99% | -3286.81% | Upgrade |
Free Cash Flow Margin | -294.49% | -41.62% | -241.47% | -630.86% | 35.05% | -1413.14% | Upgrade |
EBITDA | -137.24 | -41.18 | -120.85 | -157.89 | -155.68 | -125.81 | Upgrade |
EBITDA Margin | -210.86% | -23.13% | -200.48% | - | - | - | Upgrade |
D&A For EBITDA | 10.63 | 11.23 | 9.84 | 6.08 | 6.57 | 7.59 | Upgrade |
EBIT | -147.87 | -52.41 | -130.69 | -163.97 | -162.25 | -133.41 | Upgrade |
EBIT Margin | -227.19% | -29.44% | -216.81% | - | - | - | Upgrade |
Revenue as Reported | 65.09 | 178.03 | 60.28 | 27.15 | 6.15 | 3.96 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.